Omeros Co. (NASDAQ:OMER) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Omeros Co. (NASDAQ:OMER) has been assigned an average rating of “Moderate Buy” from the five brokerages that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $22.50.

Several research analysts recently commented on OMER shares. StockNews.com cut Omeros from a “hold” rating to a “sell” rating in a research note on Wednesday. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research report on Friday, January 17th. Rodman & Renshaw assumed coverage on shares of Omeros in a report on Thursday, November 14th. They issued a “buy” rating and a $9.00 target price on the stock. Cantor Fitzgerald reiterated a “neutral” rating on shares of Omeros in a research note on Thursday, November 14th. Finally, RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a research report on Thursday, November 14th.

Hedge Funds Weigh In On Omeros

Hedge funds have recently added to or reduced their stakes in the stock. Truvestments Capital LLC boosted its holdings in shares of Omeros by 116.5% in the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 1,669 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in Omeros by 79.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 1,972 shares during the last quarter. Quantbot Technologies LP acquired a new position in Omeros in the fourth quarter valued at $46,000. BNP Paribas Financial Markets grew its holdings in shares of Omeros by 130.6% during the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 7,016 shares during the last quarter. Finally, Picton Mahoney Asset Management increased its position in shares of Omeros by 692.5% during the fourth quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 4,404 shares in the last quarter. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

Omeros Stock Up 2.5 %

Shares of OMER stock opened at $7.66 on Friday. Omeros has a 52 week low of $2.61 and a 52 week high of $13.60. The firm has a 50 day moving average of $9.04 and a two-hundred day moving average of $7.03. The stock has a market capitalization of $443.90 million, a PE ratio of -3.32 and a beta of 2.03.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.